NASDAQ:DXCM • US2521311074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DEXCOM INC (DXCM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citigroup | Maintains | Buy -> Buy |
| 2026-03-09 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-25 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-17 | Truist Securities | Reiterate | Buy -> Buy |
| 2026-02-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-02-13 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-13 | Barclays | Maintains | Underweight -> Underweight |
| 2026-02-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-12 | Barclays | Downgrade | Equal-Weight -> Underweight |
| 2026-01-09 | Bernstein | Maintains | Outperform -> Outperform |
| 2025-12-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-11-25 | Evercore ISI Group | Initiate | In-Line |
| 2025-11-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-07 | Argus Research | Maintains | Buy -> Buy |
| 2025-11-03 | UBS | Maintains | Buy -> Buy |
| 2025-11-03 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-03 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-31 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-31 | BTIG | Maintains | Buy -> Buy |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-31 | JP Morgan | Maintains | Neutral -> Neutral |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.622B 24.49% | 4.033B 11.34% | 4.662B 15.60% | 5.337B 14.48% | 5.998B 12.39% | 6.717B 11.99% | 7.565B 12.62% | 8.329B 10.10% | 8.494B 1.98% | 9.469B 11.48% | 10.346B 9.26% | |
| EBITDA YoY % growth | 800.3M 42.66% | 871.2M 8.86% | 1.256B 44.21% | 1.612B 28.30% | 1.914B 18.73% | 2.22B 15.99% | 2.754B 24.05% | 3.007B 9.19% | N/A | N/A | N/A | |
| EBIT YoY % growth | 614.3M 51.64% | 653.5M 6.38% | 1.005B 53.73% | 1.203B 19.75% | 1.457B 21.11% | 1.748B 19.97% | 2.081B 19.05% | 2.401B 15.38% | 2.56B 6.62% | 2.893B 13.01% | 3.203B 10.72% | |
| Operating Margin | 16.96% | 16.20% | 21.55% | 22.54% | 24.29% | 26.02% | 27.51% | 28.83% | 30.14% | 30.55% | 30.96% | |
| EPS YoY % growth | 1.51 73.56% | 1.65 9.27% | 1.86 12.73% | 2.54 36.69% | 3.04 19.40% | 3.63 19.64% | 4.32 19.02% | 4.97 14.91% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.48 49.28% | 0.61 27.92% | 0.69 12.62% | 0.75 66.13% | 0.63 30.96% | 0.70 14.07% | 0.75 9.87% | 0.81 8.70% |
| Revenue Q2Q % growth | 1.199B 15.73% | 1.323B 14.34% | 1.379B 14.03% | 1.431B 13.61% | 1.402B 16.93% | 1.474B 11.41% | 1.508B 9.35% | 1.559B 8.94% |
| EBITDA Q2Q % growth | 322.47M 66.48% | 396.45M 18.13% | 438.81M 2.26% | 480.94M -27.96% | 412.03M 27.77% | 450.33M 13.59% | 456.03M 3.92% | 518.66M 7.84% |
| EBIT Q2Q % growth | 222.51M 66.42% | 291.55M 37.14% | 326.19M 34.51% | 360.42M -13.32% | 275.56M 23.84% | 324.24M 11.21% | 355.27M 8.92% | 392.94M 9.02% |
All data in USD
37 analysts have analysed DXCM and the average price target is 88.34 USD. This implies a price increase of 29.74% is expected in the next year compared to the current price of 68.09.
DEXCOM INC (DXCM) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of DEXCOM INC (DXCM) is 0.48 USD and the consensus revenue estimate is 1.20B USD.
The number of analysts covering DEXCOM INC (DXCM) is 37.